Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations

Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations

Thumbnail Image
Download
Name

nihms-977254.pdf

Description
Accepted version
Size

824.86 KB

Format

Adobe PDF

Checksum (MD5)

c7267ec26e4b568385c7ac796d6e8557

sword-2020-01-22T18:37:03.original.xml (130 B)
Original SWORD entry document
Author(s)
Khera, Amit V.
•
Chaffin, Mark
•
Aragam, Krishna G.
•
Haas, Mary E.
•
Roselli, Carolina
•
Choi, Seung Hoan
•
Natarajan, Pradeep
•
Lander, Eric Steven
•
Lubitz, Steven A.
•
Ellinor, Patrick T.
more
Date Issued
August 2018
Journal
Nature Genetics
Publisher
Springer Science and Business Media LLC
Citation
Khera, Amit V. et al. "Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations." Nature Genetics 50, 9 (August 2018): 1219-1224 © 2018 The Author(s)
Version
Author's final manuscript
Abstract
A key public health need is to identify individuals at high risk for a given disease to enable enhanced screening or preventive therapies. Because most common diseases have a genetic component, one important approach is to stratify individuals based on inherited DNA variation 1 . Proposed clinical applications have largely focused on finding carriers of rare monogenic mutations at several-fold increased risk. Although most disease risk is polygenic in nature 2–5 , it has not yet been possible to use polygenic predictors to identify individuals at risk comparable to monogenic mutations. Here, we develop and validate genome-wide polygenic scores for five common diseases. The approach identifies 8.0, 6.1, 3.5, 3.2, and 1.5% of the population at greater than threefold increased risk for coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, and breast cancer, respectively. For coronary artery disease, this prevalence is 20-fold higher than the carrier frequency of rare monogenic mutations conferring comparable risk 6 . We propose that it is time to contemplate the inclusion of polygenic risk prediction in clinical care, and discuss relevant issues.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Broad Institute of MIT and Harvard
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
http://creativecommons.org/licenses/by-nc-sa/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/125390
DOI of Published Version
https://doi.org/10.1038/s41588-018-0183-z
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.